Cargando…
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disse...
Autores principales: | Garassino, Marina C., Gadgeel, Shirish, Speranza, Giovanna, Felip, Enriqueta, Esteban, Emilio, Dómine, Manuel, Hochmair, Maximilian J., Powell, Steven F., Bischoff, Helge G., Peled, Nir, Grossi, Francesco, Jennens, Ross R., Reck, Martin, Hui, Rina, Garon, Edward B., Kurata, Takayasu, Gray, Jhanelle E., Schwarzenberger, Paul, Jensen, Erin, Pietanza, M. Catherine, Rodríguez-Abreu, Delvys |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082311/ https://www.ncbi.nlm.nih.gov/pubmed/36809080 http://dx.doi.org/10.1200/JCO.22.01989 |
Ejemplares similares
-
Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022) -
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021) -
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022) -
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023) -
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
por: Borghaei, Hossein, et al.
Publicado: (2020)